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The vocabulary currently used to describe genetic variants and their consequences 
reflects many years of studying and discovering monogenic disease with high 
penetrance. With the recent rapid expansion of genetic testing brought about by wide 
availability of high throughput massively parallel sequencing platforms, accurate 
variant interpretation has become a major issue. The vocabulary used to describe 
single genetic variants in silico, in vitro, in vivo, and as a contributor to human 
disease uses terms in common, but the meaning is not necessarily shared across all 
these contexts. In the setting of cancer genetic tests, the added dimension of using 
data from genetic sequencing of tumor DNA to direct treatment is an additional 
source of confusion to those who are not experienced in cancer genetics. The 
language used to describe variants identified in cancer susceptibility genetic testing 
typically still reflects an outdated paradigm of Mendelian inheritance with 
dichotomous outcomes. Cancer is a common disease with complex genetic 
architecture; an improved lexicon is required to better communicate amongst 
scientists, clinicians and patients, the risks and implications of genetic variants 
detected. This review arises from a recognition of, and discussion about, 
inconsistencies in vocabulary usage by members of the ENIGMA international 
multidisciplinary consortium focused on variant classification in breast-ovarian 
cancer susceptibility genes. It sets out the vocabulary commonly used in genetic 
variant interpretation and reporting, and suggests a framework for a common 
vocabulary that may facilitate understanding and clarity in clinical reporting of 








The ENIGMA consortium (Evidence-Based Network for the Interpretation of 
Germline Mutant Alleles) is an international effort focused on determining the clinical 
significance of variants in breast-ovarian cancer genes. In addition, ENIGMA 
provides expert opinion to global classification and database initiatives, notably 
ClinGen (Clinical Genome Resource; https://www.clinicalgenome.org/), ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/), and the BRCA-Exchange 
(http://brcaexchange.org/). ENIGMA also explores optimal avenues of 
communication of such information at the provider and patient level. Importantly, 
most members (65%) conduct research and clinical activities in a language other 
than English (See Supplementary Text).  
 
ENIGMA research initially focused on improvement of methods to classify BRCA1 
(MIM113705) and BRCA2 (MIM600185) variants associated with typical ‘high’ risk of 
cancer[1], with subsequent investigations identifying BRCA1/2 variants associated 
with demonstrably lower cancer risks[2 3]. The inclusion of multi-cancer syndrome 
and novel breast-ovarian cancer susceptibility genes on research and commercial 
cancer gene panels has expanded the scope of ENIGMA investigations. Four 
consecutive ENIGMA consortium meetings have included dedicated time to discuss 
appropriate terminology for describing genetic variants, and their relationship to risk 
of different cancer types, and implications for clinical management. In particular, as 
genetic test ordering has moved outside the traditional hereditary cancer clinic 
setting into mainstream oncology, concern has been raised regarding 
misinterpretation of variant pathogenicity descriptions - even for well- characterized 
genes like BRCA1/2 [4].  
  
ENIGMA members spanning all ENIGMA working groups have developed a 
document that provides an overview of different terms used in scientific and clinical 
reports, and by relevant international bodies, to describe various aspects of 
sequence variation in cancer predisposition genes. This exercise revealed 
alternative usage for many terms, interchangeable use of terms, and the potential for 
misinterpretation of the actionability of variants. We sought feedback from the 
general ENIGMA membership, by circulation of a draft discussion document and 
presentation at three consecutive consortium meetings, regarding their views on 
which terms may be most appropriate for promotion as preferred terminology in 
ENIGMA documentation, research projects and manuscripts. Discussions 
highlighted in particular the complexities of describing variant association with cancer 
risk in the context of multi-gene panel tests. Namely, that such tests may include 
genes for which “pathogenic” variants are associated with varying levels of risk for 
different cancer types, and where, even for specific genes with well-established 
hereditary cancer risk profiles, some variants may be associated with altered cancer 
penetrance compared to the “average pathogenic” variant for that gene. Different 
terms in use were considered by ENIGMA members attending the June 2016 
Consortium Meeting, to reach consensus about the least ambiguous terms for 
clinical reporting. We provide some general recommendations for terminology to 
describe cancer susceptibility gene variation and its relationship to risk. We also 
propose a multi-tier structure for reporting cancer susceptibility variants, to improve 
the understanding of level of cancer risk associated with an identified variant and 




The need for standardized terminology and definitions for describing 
sequence variation, focused on inherited variants 
 
Supplementary Table 1 summarizes terms used to describe sequence variants, 
and their association with or relevance to disease, and to patient clinical 
management. The information was derived from a combination of knowledge from 
the literature, usage in verbal and written project reporting across ENIGMA, in 
clinical reports generated or viewed by ENIGMA members, and documentation/terms 
described by the Human Variome Project (HVP; 
http://www.humanvariomeproject.org), ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) 
and International Society for Gastrointestinal Hereditary Tumours  (InSiGHT; 
https://www.insight-group.org/).  The content was presented to ENIGMA members at 
several consecutive consortium meetings, and also circulated in document form, to 
invite feedback and additions. While not claiming to be an exhaustive list of terms 
and their meanings, it is clear that a single term/phrase can be used to describe 
different aspects relating to a variant (different intent), and that multiple terms can 
describe just one aspect (same usage). In some instances, differences in 
terminology appeared to depend on the field of research, and the context in which a 
variant is identified. Notably, the term “pathogenic variant” is used to describe a 
germline disease-causing variant in a Mendelian disease gene classified according 
to criteria from the American College of Medical Genetics and Genomics/ 
Association for Molecular Pathology (ACMG/AMP) [5] or  International Agency For 
Research On Cancer (IARC) [6]. It has also been described as a “sequence variant 
that contributes mechanistically to disease but is not necessarily fully penetrant i.e. 
may not be sufficient in isolation to cause disease” in the context of assessing 
support of disease causality of variants identified by high throughput sequencing [7]. 
Moreover, a germline “pathogenic variant” considered causal for disease risk is 
commonly termed a “mutation” in the historical and even current literature, and in the 
medical management (National Comprehensive Cancer Network, www.nccn.org; 
National Institute for Health and Care Excellence, https://www.nice.org.uk; EviQ, 
https://www.eviq.org.au) and research setting [8]. However, “mutation” can refer to 
any permanent change in DNA sequence (irrespective of frequency or disease-
causing potential), and “mutation” is used almost exclusively to describe somatic 
variation in the context of tumorigenesis. Indeed, the interface of the CIViC (Clinical 
Interpretation of Variants in Cancer) knowledgebase [9] describes variants for a 
specific gene using the term “mutation”, with additional qualifications e.g. for TP53 
(MIM191170), the qualifiers include: deleterious, DNA binding domain, truncating. To 
add to the complexity, the Leiden Open Variation Database (LOVD) freeware 
database software [10], promoted widely for sharing and curation of (germline) 
disease gene variants, describes the equivalent of variant pathogenicity as “variant 
effect”. The most current version LOVD3 prescribes the terms “affects function” 
instead of “pathogenic”, and the following terms for four other pathogenicity classes: 
“probably affects function”, “unknown (or effect on function not known)”, “probably 
does not affect function (or probably no functional effect)”, and “does not affect 
function (or no functional effect)”. 
 
Further, feedback from ENIGMA consortium members indicated there was varied 
perception of the level of risk association and clinical actionability for variants 
described as “Benign” or “Not Pathogenic”, terms put forward by the ACMG/AMP [5] 
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and IARC [6] classification schemes, respectively, to indicate that a variant is not 
clinically actionable for patient management.  Also, the distinction between a variant 
described as uncertain (ACMG/AMP and IARC - reviewed and insufficient or 
conflicting evidence regarding pathogenicity) versus unclassified (not yet assessed) 
[11] was poorly recognized.  
 
In addition, we separately documented terms used to describe output from some 
more commonly used bioinformatic prediction tools (Table 1), since results from 
bioinformatic analysis are almost always included in clinical test reports. Such 
bioinformatic predictions are generally defined without reference to clinical 
information, are often binary, and are intended to be included as one of several 
points of information used to arrive at a final variant classification. Nevertheless, we 
identified several possibilities for misinterpretation of bioinformatic output terms as a 
“final” variant classification. The PolyPhen2 tool [12] uses the term “benign” to 
describe variants with no/little predicted effect on protein function – the same as the 
ACMG/AMP term for a variant that is not considered important for 
diagnosis/risk/patient management. Of greater concern, the term “deleterious” is an 
output from multiple tools (CONDEL, LRT, Mutation Taster, Provean); this term is 
also used by the European Medicines Agency (EMA; http://www.ema.europa.eu/) 
and the US Food & Drug administration (FDA, https://www.fda.gov/) to denote 
eligibility of patients with specified cancer types/presentation for PARP inhibitor 
therapy, namely patients with a “deleterious or suspected deleterious germline [or 
somatic] BRCA mutation”. Further, the combined term “deleterious mutation” is used 
(in addition to the term “pathogenic mutation”) by the NCCN 2018 guidelines 
(www.nccn.org) to describe genetic variation used to denote specific management 
recommendations for familial breast-ovarian cancer patients. Without clarity of the 
use of these terms in context, there is significant risk of overinterpretation of 
bioinformatic data. Cancer genetic germline tests are increasingly being ordered by 
clinicians relatively unskilled in genetic terminology. A clear reporting language, with 
clear definitions of final variant interpretation summarizing all the component 
information used for classification, is thus paramount to avoid variant 






Table 1: Text descriptors from selected bioinformatic prediction programs used for variant annotation in 
sequencing pipelines.*  
Program Output terms and other descriptions  
CONDEL  
(CONsensus DELeteriousness 





Description: The scores of different methods (SIFT, Polyphen2, 
Mutation Assessor, FATHMM, Ensembl-variation) are weighted 
using the complementary cumulative distributions of 
approximately 20.000 missense SNPs, both deleterious and 
neutral.  
FATHMM 
(Functional Analysis through 




LRT (Likelihood ratio test) Deleterious  
Disease-Causing (identified in a “mutation database”) 
Polymorphism (predicted OR annotated) 
http://www.genetics.wustl.edu/jflab/lrt_query.html 




Mutation Assessor Predicted non-functional (low, neutral) 
Predicted functional (low, neutral) 
http://mutationassessor.org 
nsSNPAnalyzer 
































* NOTE: Prediction tools used for missense variants highlighted in grey are included as options for scoring 
bioinformatic predictions in the ClinGen Pathogenicity calculator [13] (http://calculator.clinicalgenome.org/site/cg-
calculator), and the ClinGen Variant Curation Interface (https://curation.clinicalgenome.org/), both developed 
to enable application of the ACMG/AMP guidelines. The meta-predictors REVEL (Rare Exome Variant 
Ensemble Learner) [14], CADD (Combined Annotation Dependent Depletion) [15], and BayesDel [16], provide 
continuous scores and not specific terms as output. Output terms also used in clinical reporting, or to define 




Proposed vocabulary to describe genetic variation in cancer predisposition 
genes  
 
The terms discussed below primarily focus on describing germline variation in cancer 
genes, detected by genetic testing for diagnosis of hereditary cancer or estimating 
future cancer risk. However, the vocabulary inevitably overlaps terms used to 
describe somatic variation in tumors in the context of drug therapy selection for 
cancer patients, or distinguishing true germline variants from variants arising from 
somatic clonal drift in “disease free” tissue used for DNA extraction [17 18]. These 
suggestions take into consideration terms put forward by the IARC unclassified 
sequence variants working group [6], ACMG/AMP [5] and HVP [19], and a 
comprehensive review article assessing clinical implications of gene panel test 
results for breast cancer risk prediction [20]. We have not addressed variant 
annotation in relation to predicting response to drug treatment. We refer readers to 
the Clinical Pharmacogenetics Implementation Consortium for consensus terms for 
reporting clinical pharmacogenetic results [21], and note that ClinVar currently 
supports the following terms describing variant effect relating to therapy: drug 
response, confers sensitivity. For any given variant, the term wild-type may be used 
to denote the nucleotide/s or amino acids in the selected reference DNA/protein 
sequence. However, this term can also be used to describe “normal” phenotype, 
typically protein function/characteristics measured by in vitro assays. 
 
The term variant should be used to define a DNA change that differs from a defined 
reference sequence, consistent with recommendations from the ACMG/AMP [5] and 
HVP [19]. Various descriptors of a variant depend on the context, as denoted below. 
 
 
Cellular Origin of Variant 
 
It is important to specify the tissue from which tested DNA has been derived, 
irrespective of the use of the descriptors below. 
 
 Constitutional or Germline (used interchangeably) - a sequence variant 
identified in DNA from a tissue type assumed to represent the DNA content of the 
fused germ cells (e.g. blood), and therefore to be transmittable to offspring. This 
includes a sequence variant that arises de novo in a gamete and in this setting 
will be present in all cells of an individual but not inherited from one or other 
parent. 
 Mosaic - sequence variant that has arisen during embryogenesis and therefore 
not present in all the cells/tissues of an individual. 
 Somatically acquired (not inherited) – sequence variant present only in a 
specific tissue. In the context of tumor DNA (tumor biopsy or circulating tumor 
DNA derived from blood), the variant will be present in tumor DNA and absent 
from DNA derived from other tissue/s of the same individual.  
 Somatically-detected - sequence variant detected in a specific tissue type and 
for which somatic or germline origin has not yet been established by investigating 
DNA from other tissues. May be used for variation detected by tumor sequencing 
(tumor-detected), or in the context of suspected mosaicism. Somatically-
detected variants identified in DNA from blood/saliva with allele proportion <0.3, 
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and/or in individuals with incompatible clinical presentation, are more likely to 
represent variation due to aberrant clonal expansion in hematopoetic cells 
(particularly TP53 [17 18]), or from circulating tumor DNA. 
 
Nucleotide-level evolutionary conservation 
 
Nucleotide sequence changes in coding regions are primarily assessed using 
protein-level conservation analysis that assesses their effect on protein sequence 
(see below).  However, nucleotide-level conservation analysis may be considered 
useful for investigating effect of sequence changes on the fitness of splicing 
regulatory motifs, or mRNA secondary structure and stability, translation efficiency 
[22-24], or to infer functional importance of non-coding sequences (introns, 
untranslated regions and other extragenic sequence). Indeed, it is a factor denoted 
for review of synonymous variants (code BP7) in the ACMG/AMP guidelines [5].  
 
Nucleotide substitutions analyzed by evolutionary/phylogenetic methods involve 
alignment of at least three nucleic acid sequences, termed multiple (multi-species) 
sequence alignment (acronym MSA). We suggest that such analysis specify the 
method/program used, the number of ortholog sequences included, and their 
phylogenetic relationship to humans. To our knowledge, there are no firm standards 
proposed for use of nucleotide-level evolutionary conservation in predicting whether 
a variant may affect fitness of difference sequence motifs (splicing, transcription 
factor binding etc).  
 
We thus suggest that nucleotide positions in the alignment may be described simply 
as:  
 Evolutionarily invariant – at the position of the variant, the MSA is identical 
across all species considered in the alignment 
 Evolutionarily variant - at the position of the variant, the MSA is not identical 
across all species considered.  
Scores provided by specific tools, eg PhyloP [25], may be helpful to assess if a 
specific position is evolutionary constrained or not [26].  
 
Further, position weight matrices [27] developed for functionally important sequence 
motifs eg splice junctions [28] may be useful to gauge the effect of a genetic variant 
on the fitness of that sequence motif. 
 
 
Protein-level evolutionary conservation and bioinformatically predicted 
physicochemical characteristics of a missense alteration 
 
As noted above (Table 1), bioinformatic tools use a range of terms to describe 
results from analysis of a given predicted missense alteration. Protein-level 
conservation analysis is required to adequately capture redundancy in codon usage, 
and additional features considered include relative physicochemical properties of 
amino acids, and predicted effects on protein secondary, tertiary and quaternary 
structure. Without prescribing or recommending use of any particular tool/s for 
variant evaluation, we do recommend use of the following terms to describe output 
for analysis of missense substitutions (or small in-frame insertions/deletions) using 
evolutionary/phylogenetic methods. Depth of the analysis for a protein sequence 
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alignment should be specified, including number of ortholog sequences in the protein 
multiple sequence alignment (PMSA), phylogenetic relationship of the species most 
evolutionarily distant to humans, and the average number of substitutions per 
position [29].  
 
Variants should be described in relation to the level of evolutionary conservation for 
that amino acid position (residue) in the protein multiple sequence alignment (and 
noting that the non-human sequences included in the alignment should be wild-type 
(the form that occurs most frequently) and of a splice form matching the human 
reference sequence, insofar as possible). 
 
Generic descriptors for an amino acid position (residue) in an alignment: 
 Evolutionarily invariant – amino acid at that position in the PMSA is identical 
across all species considered 
 Evolutionarily conserved - amino acids at that position in the PMSA have 
similar* physicochemical properties across all species considered.  
 Not evolutionarily conserved - amino acids at that position in the PMSA show 
marked differences* in physicochemical properties across the species 
considered. 
*There are alternative methods to assess similarity and differences for substitutions 
at a given position in a multiple sequence alignment. The method should be defined 
for the specific analysis conducted. Examples include: Grantham Variation (GV) is 
<60 (conserved) or ≥60 (not conserved); residue harbours an alternate amino acid 
with Grantham Difference (GD) score <60 (conserved) or residue variation exceeds 
this limit (not conserved)[30]. 
 
Descriptors for an amino acid change relative to the sequence alignment: 
 Outside the range of variation (observed evolutionarily) – altered amino acid 
has markedly different physicochemical properties (defined by size, charge etc) 
to the range of variation of those properties observed at its position in the PMSA.  
Note: this is relatively more likely to happen if the position is invariant or 
conserved. 
 Similar to the range of variation (observed evolutionarily) - altered amino 
acid has similar physicochemical properties to the extremes observed for the 
range of variation of physicochemical properties at that position in the PMSA e.g. 
GV>0 and GD relatively small, say <30. 
 Inside the range of variation (observed evolutionarily) - altered amino acid 
has physicochemical properties that clearly fall within the range of variation of 
those physicochemical properties observed at that position in the PMSA e.g. 
GV>0 and GD=0. 
 
If the position of an amino acid variant in the PMSA is invariant or conserved, and 
the change is outside the range of variation, then it is considered evolutionarily 
unlikely.  Conversely, an amino acid substitution that is within or similar to the range 
for variation observed evolutionarily, may be termed evolutionarily tolerated (if the 
alternative amino acid is already present in the alignment) or otherwise 
evolutionarily tolerable (if the alternative amino acid is not observed in the 




As noted above, bioinformatic prediction of variant effect on function should not be 
used alone to infer association with measurable disease risk. However, variant 
effect/bioinformatic prediction scores, together with information on variant location in 
the gene relative to splicing motifs/functional domains, may be calibrated against 
clinical measures of variant pathogenicity (termed clinical calibration) to provide 
probability estimates useful to re-assign a variant as likely not pathogenic [31-34]. 
See Supplementary text for more details. 
 
 
Impact on mRNA transcript profile or protein function  
 
mRNA profile:  
 
We recommend “naturally-occurring mRNA transcript” be used to describe mature 
mRNA transcript/s seen in controls. Using mRNA transcription in control samples as 
reference, a variant may exhibit an altered mRNA transcript profile by:  (i) impacting 
overall level of transcript/s (overall expression); (ii) resulting in novel mature mRNA 
transcript/s; and/or   (iii) altering the relative contribution of individual transcripts to 
the overall expression. Control mRNA should be from the same tissue type and 
analyzed using the same methodology.  
 
Variants assessed for effect on transcription via gene regulation, may be described 
as not impacting transcription levels, or impacting transcription levels. Impact on 
transcription can be further described as partial, or total (also termed transcriptional 
silencing). Epigenetic silencing specifically refers to impact on transcription via 
altered methylation profile. 
 
Variants assessed for effect on mRNA transcript profiles via impact on mRNA 
splicing, including loss, gain or enhanced use of cryptic splicing motifs, may be 
described as follows: 
 Non-spliceogenic - the variant does not alter mRNA transcript profile. 
 Spliceogenic (predicted) LOF – the variant results in an altered mRNA 
transcript profile that is predicted to cause gene loss-of-function i.e. any 
combination of mRNA transcripts predicted non-coding, predicted protein 
truncating-NMD, and/or predicted to encode proteins lacking critical 
structural/functional motifs.     
 Spliceogenic (predicted) functional - the variant results in an altered mRNA 
transcript profile that is predicted to preserve gene functionality i.e. any 
combination of mRNA transcripts which together will encode protein/s that is/are 
predicted to preserve functional capacity. 
 Spliceogenic uncertain function – the variant results in an altered mRNA 
transcript profile for which the coding/functional consequences are uncertain i.e. 
combinations of transcripts predicted to cause gene loss-of-function, retain gene 
function, or to encode proteins with uncertain functional potential, for which the 




Variants that have been analyzed in functional (biochemical, biophysical, molecular 
biological) assays that assess variant effect on protein conformation/activity/function 
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should compare effect (always specifying effect measured) to wild-type and other 
controls as follows: 
 No functional impact - variant displays features (specified) similar to wild-type. 
 Functional impact - variant alters features (specified) compared to wild-type. 
Impact may be described as:  
o Complete loss of function - variants with loss of function (feature to be 
specified) below a detection threshold or to a degree of the average 
pathogenic variant for that gene/protein. 
o Partial loss of function - variants with partial loss of function (feature to be 
specified) i.e. intermediate between that of the wild-type protein sequence 
and the average pathogenic variant for that gene/protein. May alternatively 
be described as intermediate functional effect or hypomorphic.  
o Gain-of-function – term encompasses increase in a known function for that 
protein relative to wild-type, or gain of additional novel functions e.g for p53 
[35], RET [36]. May alternatively be described as neomorphic.  
o Dominant-negative – variant that encodes an altered protein that interferes 
with the function of the protein encoded by the wild-type allele. A common 
example is a variant encoding a protein that retains the ability to form protein-
protein complexes, but disrupts the functionality of such complexes. 
 
 
Note: A variant with measurable effect in vitro on mRNA transcript profile or protein 
function (specifying feature measured), relative to appropriate controls, should not be 
assumed to be associated with disease risk. To include functional and mRNA data in 
gene-specific variant classification protocols, it is necessary that the association 
between magnitude of effect on mRNA profile/protein function and disease risk is 
first calibrated against clinical measures of variant pathogenicity, such that the range 
of variation in effect is established for variants previously classified as pathogenic, 
and for those considered not pathogenic. See [37 38] for example calibration of 
BRCA1 and BRCA2 transcript levels. 
 
 
Genetic variation and description of associated disease risk 
 
Cancer risks associated with a genetic variant may be presented in a variety of 
different ways. Risk associated with a proven cancer-predisposing gene variant 
(type) can only be correctly interpreted if the time period and population to which the 
risk applies is defined [39]. Most cancer predisposition genes exhibit organ-specific 
disease expressivity, so it is important to specify disease (phenotype), and mode of 
inheritance. A given variant may confer different disease risks for heterozygote 
versus compound heterozygote or homozygote carriers. 
 
 Absolute or Cumulative risk is the likelihood that a person with a cancer-
predisposing variant will develop a given cancer within a period of time e.g. within 
the next 5 or 10 years, or by a specific age. It is expressed as a percentage. 
 Relative risk compares the cancer risk for genetic variant carriers relative to the 
risk for non-carriers or the general population, and can be estimated through 
several study designs e.g. case-control studies estimate Odds Ratios, cohort 
studies estimate Rate Ratios.  
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 Disease penetrance is typically used to describe the overall probability that 
carriers of cancer-predisposing variants in a given gene (sometimes specifying a 
specific variant type) will develop specified cancer type/s until a specified age or 
during lifetime. For a fully penetrant genetic variant (or variant type), disease will 
develop in all individuals with the variant (type). Reduced penetrance may be 
used to describe a variant that displays lower penetrance compared to risk-
associated variants typically identified for that disease gene. The estimated level 
and type of disease risk/s associated with a reduced penetrant variant determine 
whether carrier status may be used to inform clinical management.  
 
We suggest that it is helpful to present variant-associated risks to patients as both an 
absolute measure (e.g. 50 in every 100 people with this variant (type) are expected 
to develop breast or ovarian cancer by age 70) and a relative measure (e.g. a variant 
carrier is 10 times more likely to develop breast cancer in their lifetime compared to 
women in the general population), and report these with appropriate confidence 
intervals. Based on descriptors applied previously for breast cancer [20], for this 
discussion document we have categorized cancer risk levels associated with a given 
variant, relative to the general population risk, as follows: High increased risk, >4-
fold; Moderate increased risk, 2-4-fold; Low increased risk, greater than unity and 
<2-fold. Relative risks are not clinically useful without knowing the absolute risk of a 
disease – a relative risk of four for a rare disease is still a small risk. A high relative 
risk is not necessarily a high absolute risk because the latter depends on the 
baseline population risk. Thus, for cancer types that are uncommon in the 
population, the absolute risk, and also the availability of interventions, have to be 
considered when determining the clinical actionability of a variant. Note, the term 
“intermediate” requires reference values to define its level (for relative or absolute 
risk), and is thus considered non-specific for the purpose of variant reporting. 
 
The term risk allele may be used as an alternative to describe a variant identified as 
cancer-associated, generally using case-control analysis such as genome-wide 
association studies, where there is not necessarily a mechanistic relationship 
between a “lead” variant in a linkage disequilibrium block and disease predisposition. 
 
 
Proposed vocabulary to describe clinical relevance of genetic variation in 
known or suspected cancer predisposition genes using a 5-tier system 
 
The IARC 5-tier variant classification system was developed to promote use of 
probability-based methods for variant classification of highly penetrant cancer 
susceptibility genes that could then be specifically linked to recommended clinical 
management protocols [6]. This system has been adopted by the InSiGHT group for 
mismatch repair (MMR) gene variant classification [40], and by ENIGMA for 
BRCA1/2 variant classification (https://enigmaconsortium.org). It is used for ClinGen-
approved expert panel curation of variants in these genes, displayed in ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/) and selected public locus-specific databases 
(https://www.insight-group.org/variants/; http://brcaexchange.org/). The IARC tier 
terminology and management recommendations as published in 2008 are broadly 
consistent with those recommended by ACMG/AMP (See Table 2). However, 
assigning terms for the variant tiers across different public portals has highlighted 
differences in the wording used to describe the IARC Class 2 and Class 1 tiers, and 
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potential for misinterpreting the clinical relevance of individual variants based on 
current IARC or ACMG/AMP terms. Indeed, misinterpretation of the Class 1 tier has 
been raised in relation to the BRCA2 c.9976A>T p.Lys3326Ter variant associated 
with less than 1.5-fold increased risk of breast or ovarian cancer [41], both publicly 
[42 43], and by direct query to the BRCA-Exchange website 
(http://brcaexchange.org/). The latter led to a change in representation of this tier as 
“benign” to “benign-little clinical significance” on the BRCA-Exchange website. 
 
Further, during development of the ENIGMA BRCA1/2 variant classification criteria 
(https://enigmaconsortium.org), research results emphasized the need for clear 
statements about appropriate class assignment for variants with proven association 
with so-called “intermediate” or “moderate” increased risk of cancer. Specifically, 
discovery that the BRCA1 c.5096G>A p.Arg1699Gln variant demonstrates reduced 
disease penetrance relative to “high-risk” truncating BRCA1 variants raised the issue 
of how to denote such reduced penetrance variants in the 5-tier system, in particular 
if the disease penetrance was sufficient to trigger altered management albeit not as 
extensive as the “standard pathogenic” variant for that gene [3]. The advent of multi-
gene panel testing that encompasses so-called “moderate-risk genes” has further 
highlighted the complexities of trying to develop and implement simple terms to 
describe the disease risk and clinical relevance of variants where risk by variant type 
can differ between and within genes. Indeed, circulation and discussion of the 
ENIGMA terminology highlighted “pathogenic” as the term for which the definition 
was most contentious. 
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Table 2:  Alternative terms currently in use to describe 5-tier disease gene variant classification categories 
IARC Classification Scheme [6].  
Intended use, highly penetrant cancer susceptibility genes 
ACMG/AMP [5]. 















Description of Clinical Relevance 
Class 5 Definitely 
Pathogenic** 
>0.999 Yes Full high-risk surveillance 




>0.999 Variant classified as pathogenic using the 
proposed classification scheme has met 
criteria informed by empirical data such that 
a health-care provider can use the molecular 
testing information in clinical decision making 
Class 4 Likely 
pathogenic 
0.950-0.999 Yes Full high-risk surveillance 




0.900-0.999 Sufficient evidence that a health-care 
provider can use the molecular testing 
information in clinical decision making when 
combined with other evidence of the disease 
in question. 






Based on family history & 
other risk factors  
Uncertain 
Significance 
0.100-0.899 Should not be used in clinical decision 
making; efforts to resolve the classification of 
the variant as pathogenic or benign should 
be undertaken 
Class 2 Likely not 
pathogenic or 








Treat as “no pathogenic 
variant detected” for this 
disorder (i.e.based on family 




0.001-0.099 Sufficient evidence that a health-care 
provider can conclude that it is not the cause 
of the patient’s disorder when combined with 
other information 
Class 1 Not 
pathogenic or 
of no clinical 
significance§ 
<0.001 No Treat as “no pathogenic 
variant detected” for this 
disorder (i.e.based on family 
history & other risk factors) 
Benign <0.001 Sufficient evidence that a health-care 
provider can conclude that it is not the cause 
of the patient’s disorder. 
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* represented with minor modifications for clarity (words in parentheses) introduced by the ENIGMA consortium 
** represented as “Pathogenic” by InSiGHT, ENIGMA, and on the BRCA Exchange website (http://brcaexchange.org/)  
† represented as “Uncertain Significance” on the BRCA Exchange website (http://brcaexchange.org/)  
†† represented as “Likely Benign” on the BRCA Exchange website (http://brcaexchange.org/). 
§ represented as “Benign / Little Clinical Significance” on the BRCA Exchange website (http://brcaexchange.org/)  




In an attempt to address all the above issues, we considered usability of terms in 
research publications, inconsistencies in wording for the IARC Class 1 and 2 [6], and 
alignment with terminology recommended by the ACMG/AMP guidelines [5]. We also 
considered relevant definitions from several English dictionaries, and the derivation 
of the word (See Supplementary text) - this being an important component of 
translating meaning of terms by collaborators for whom English is not the first 
language. 
 
During the ENIGMA meetings held January 2017, September 2017 and June 2018, 
the ENIGMA membership have been presented with various options for describing or 
rewording terms, with more detailed descriptions of each of the 5 tiers intended to 
capture the complexity of reporting in the multi-gene panel testing era. Discussions 
arising from these presentations, and additional commentary on documentation 
circulated to members, has resulted in the recommendations and summary 
descriptions shown in Table 3. We anticipate that this more detailed description of 
the clinical implications of, and management recommendations associated with, 
germline variants placed in each of the classification tiers will provide a short-term 
solution to improve understanding of these terms in the context of clinical reporting of 
cancer predisposition variants using a 5-tier classification system. Adaptation for 
other Mendelian or co-dominant disease genes is possible, subject to clear definition 
of level of disease risk associated with clinical actionability, and other factors to be 





Table 3:  Recommended terminology and descriptors for 5-tier disease gene variant classification categories, considering variant pathogenicity in the multi-gene 









Generic description of 
cancer risk determined for 
the variant 
Generic description of relevance to clinical management for germline variants in cancer 
susceptibility genes 
High penetrant variants 
 (>4-fold risk relative to population) 
Moderate penetrant variants 
 (2-4-fold relative risk) 
Class 5 Pathogenic P Sequence variant is 
associated with ≥2-fold 
cancer risk, and could be 
used to inform medical 
management. 
Sequence variant may be used alone to inform 
clinical management. Management 
recommendations for an individual should be 
determined in accordance with absolute risk of 
specified cancer types, considering clinical 
presentation and other known genetic and 
environment risk factors.** 
Offer predictive testing for relatives. 
Clinical management recommendations for a 
variant carrier should consider knowledge of 
personal and family history of disease, and 
other known genetic and environmental risk 
factors, that together can strongly influence 
absolute risk for an individual.*** 
Consider predictive genetic testing for relatives 
only if supported by local (regional/national) 
guidance 
Class 4 Likely 
Pathogenic 
LP Sequence variant is likely** 
associated with ≥2-fold 
cancer risk, and could be 
used to inform medical 
management. 
As above - Sequence variant may be used 
alone to inform clinical management. Consider 
other factors to refine estimate of absolute risk 
for an individual. 
As above - Sequence variant should be used to 
inform clinical management only after 
consideration of other factors with influence 
absolute risk for an individual.*** 
Class 3 Uncertain 
(Significance) 
VUS Sequence variant has been 
assessed for association with 
cancer phenotype/s but risk 
association remains 
uncertain. 
Clinical management recommendations should be determined on the basis of personal and/or 
family history of disease, and other known genetic and environmental risk factors.*** The 
presence of the variant should not be used to influence management of the carrier individual or 
their relatives. 
Research testing of family members may be recommended to aid variant classification. 




LB Sequence variant is likely 
NOT associated with ≥2-fold 
cancer risk. 
Variant on its own is likely to be of no or little clinical significance. Clinical management 
recommendations should be determined on the basis of personal and/or family history of disease, 
and other known genetic and environmental risk factors.*** 
Further research may clarify variant contribution (if any) to risk. 





Sequence Variant is NOT 
associated with ≥2-fold 
cancer risk. 
Variant on its own is of no or little clinical significance. Clinical management recommendations 
should be determined on the basis of personal and/or family history of disease and other known 
genetic and environmental risk factors.*** 
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* The tier descriptions have been adapted to: allow for  both high and moderate-risk variants (irrespective of the gene involved) to be annotated for medical actionability in accordance with the 
level of risk/s they impart to individual carriers;  consider that relative risks are age-specific for common diseases such as cancer where incidence in the general population increases with 
increasing age, so the relative risk associated with a cancer predisposition gene falls with increasing age; denote specifically that clinical management recommendations should consider 
personal and family history of disease, as well as environmental exposures, and other genetic risk factors (in particular polygenic risk score information).Terminology assumes that only 
variants associated with a relative risk of >2-fold will be reported out as unique variants with directly assigned pathogenicity. 
** Defined as 90% (ACMG/AMP) or 95% (IARC) certainty of being pathogenic or benign. As per IARC recommendations [6], further research, including research testing of family members, may 
be helpful to better determine the risk association and clinical significance of the variant. 
*** Other factors may reduce or increase the risk of disease. Risk factors to be assessed may include polygenic risk scores, which themselves include information about individual variants 
associated with <2-fold risk (low increased risk). Note, inclusion of both family history and polygenic risk score information for absolute risk estimation should account for the proportion of 
familial relative risk that is explained by genetic factors included in the polygenic risk score calculation [44]. Further implementation research is required to understand how best to implement 
PRS testing to stratify cancer risks in a range of settings, including cancer patients and general population screening.  
† The combined text description was selected as preferable for initial presentation in reporting, to underscore the fact that some sequence variants falling into class 1 or class 2 may be causally 
associated with a defined low increased risk of cancer e.g. the BRCA2 c.9976A>T p.(Lys3326Ter) variant associated with less than 1.5-fold increased risk of breast or ovarian cancer [41]. 
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Proposal for development of a multi-tier system for variant annotation in 
clinical test reporting of multi-gene panel results 
 
Despite the expansion of descriptions for the 5-tier variant classification system 
shown in Table 3, it was clear from comments received that assignment of variant 
pathogenicity using the current 5 tier system is inadequate to deal with the 
complexities of reporting multi-gene panel testing outcomes, and to portray 
differences in variant-specific risks for a given gene. The term “pathogenic” remained 
contentious, with comments raised by ENIGMA members including: need to capture 
the relevance of genetic findings to patient disease diagnosis (phenotype) versus 
relevance of a secondary finding (i.e. outside of the patient diagnosis); reporting 
variant effect for recessive as well as dominant disease; and whether a variant could 
be termed “pathogenic” on the background of a polygenic risk score that reduced 
individual risk to the population level. These observations indicate a need for a more 
consistent approach to variant reporting for clinical use, to minimize ambiguity of 
clinical management considerations. We thus developed a template to emphasize 
the value of  a multi-tier reporting system, (outlined in Table 4), and provide several 
worked examples (Supplementary Table 2) to indicate its potential to capture the 
complexity of clinical actionability for variants identified by multi-gene cancer panel 
testing. The intention is that clinical inferences should be added to specific variant 
interpretation/classification, requiring the report to capture the level of (un)certainty 
around risk estimates and the contribution of an individual reported variant to a 
composite risk score. This could then be linked to clinical discussions about potential 









Table 4: Suggested approach to multi-tier reporting of cancer gene variants conferring high or moderate disease risk* 
 
 
Demographic Information  
Cancer Phenotype <specify cancer phenotype of proband> 
Sample Tissue □ Blood   □ Saliva   □ Primary Tumour   □ Distant Metastasis   □ Other 
Context □ Diagnostic   □ Prediction Cancer Risk   □ Genotype Directed Treatment   □  Other (specify) 
 
Variant Identified  Variant description should be based on the Human Genome Organisation (HUGO) standard variant nomenclature and Human Genome Variation Society (HGVS). 
The use of HGVS nomenclature can be problematic for describing exon deletions/duplications (particularly where endpoints are unknown) and triplet repeat 
expansions. Therefore such variants should also be described in words if this improves clarity.  
 
Level 1: Variant Classification* Variant interpretation by the laboratory – variant classification based on all available data 
ACMG/AMP or IARC Variant 
Classification 
Pathogenic or Likely Pathogenic or Uncertain Significance or Likely Little Clinical Significance/ Likely Benign or Little Clinical Significance / Benign 
Assertion relates to dominant mode of inheritance for cancer phenotype. 
Details of the evidence supporting the variant classification are provided as supplementary documentation.  
 
Level 2: Clinical Validity* Considers the strength of evidence for the genetic variant being related to the presenting cancer phenotype, new primary cancer risk, predicting the likely response to 
targeted treatment, or relevance to recessive phenotypes. It is recognised that specific missense and protein truncating variants within the same gene may exhibit a 
differing magnitude of effect on cancer risk. 
Presenting Cancer Phenotype There is strong evidence that this variant is making a (substantial) contribution to the presenting cancer phenotype <insert reference>. 
or  
There is insufficient evidence to support an association between this variant and the presenting cancer phenotype <insert reference if available>.** 
Prediction Cancer Risk There is strong evidence to support the prediction of a high (>4 fold) increase in future cancer risk <specify cancer type/s> when this variant is present in a family 
member (reference with associated risks). 
or 
There is strong evidence to support a moderate (2-4 fold) increase in future cancer risk <specify cancer type/s> when this variant is present in an family member and 
can be used for cancer risk stratification. This variant should not be considered in isolation. Information from the family history of disease, and other known genetic 
and environmental risk factors or polygenic risk scores may substantially modify overall cancer risk estimates < insert reference with associated risks>. 
or 
There is strong evidence from population studies to support that is variant is associated with a low (<2-fold) increase in cancer risk <specify cancer type/s> 
<reference with associated risks>. This variant is insufficiently predictive of future risk to be clinically actionable. Variants in this category may contribute towards a 
polygenic risk score. 
Genotype Directed Treatment There is evidence to support consideration of <specify drug/drug type> in the context of <specify cancer type> <insert reference/s>*** 
or 
There is currently <limited/no> evidence to support consideration of <specify drug/drugtype> in the context of <specify cancer type>  





Level 3: Clinical Utility & 
Actionability* 
This final element comprises the discussion between physician and patient. It may take the form of a personalised assessment of risk based upon the presenting 
cancer phenotype, clinical scenario and family history. If the reporting laboratory is not qualified to address this element of the report then it should be made clear that 
this is an additional requirement before determining any clinical management consequences.  Proposed clinical interventions should be risk proportionate and take 
the individual clinical circumstances into account reflecting on any uncertainty around estimates of risk underpinning life changing decisions such as risk reducing 
surgery or reproductive choices. It also requires consideration of cascade genetic testing for other relatives at risk. If preferred, the report may be shortened by 
referring to local guidelines for details. 
(i) Clinically actionable  
(High penetrance) 
Simplified report: Follow clinical management guidelines for high penetrance predisposition genes according to local guidelines 
 
Or Detailed report presenting details from local guidelines – EXAMPLE provided:  
1. Surveillance: High risk surveillance if strong evidence for variant-specific high risk  
2. Risk Reducing Surgery: Consider risk reducing surgery only if the overall clinical picture is high risk (see above) and depending on cancer prognosis and 
treatment <specify appropriate risk reducing surgery>.  
3. Cascade Genetic Testing: Sequence variant may be used alone to inform clinical management and so cascade genetic testing is indicated. 
(ii) Clinically actionable but not in 
isolation 
(Moderate penetrance) 
Simplified report: Manage Based Upon a Comprehensive Risk Evaluation + 
Additional moderate or high risk surveillance may be indicated. Clinical management recommendations should be determined on the basis of the absolute cancer 
risks conferred by <variant identified> in combination with the personal and/or family history of disease and other known genetic and environmental risk factors. 
Follow clinical management guidelines according to local guidelines 
 
Or Detailed report presenting details from local guidelines  - EXAMPLE provided:  
1. Manage Based Upon a Comprehensive Risk Evaluation + : Additional moderate or high risk surveillance may be indicated. Clinical management 
recommendations should be determined on the basis of the absolute cancer risks conferred by <variant identified> in combination with the personal and/or family 
history of disease and other known genetic and environmental risk factors. 
2. Risk Reducing Surgery: For moderate penetrance gene variants in isolation, there is currently no clear evidence of clinical benefit for risk reducing surgery. 
3. Cascade Genetic Testing: Predictive testing for this variant has limited clinical utility in isolation. 
(iii) Not clinically actionable  
(Low penetrance) 
Manage Based Upon Family History 
Insufficiently predictive of future cancer risk to be clinically actionable. Clinical management recommendations for the <presenting cancer phenotype> should be 
determined on the basis of personal and/or family history of disease and other known genetic and environmental risk factors. Variants in this category may contribute 
towards a polygenic risk score. 
+High risk surveillance if comprehensive cancer risk (family history based risk) stratification >30% absolute lifetime risk, moderate risk surveillance if comprehensive cancer risk stratification (family history based risk) 17-30% 
absolute lifetime risk, population screening if comprehensive cancer risk stratification (family history based risk) <17% absolute lifetime risk. 
* We suggest that this should be repeated for each reportable variant identified in the sample submitted (usually the proband - defined as the person serving as the starting point for the genetic study of a family; may be a 
cancer patient or not). For high risk cancer susceptibility genes the probability threshold for classification as Likely Pathogenic  is 0.95 for the IARC classification scheme [6] and 0.90 for the ACMG/AMP guidelines [5]. It may 
be reasonable to consider the 0.90 threshold as more appropriate for moderate penetrance variants, where recommended management excludes irreversible surgical risk-reducing strategies. We suggest that only strong 
evidence supporting risk associations should be used to determine clinical validity of clinically actionable variants. We define strong evidence following recommendations published in [20], namely: “we consider it to be likely 
that a given risk will be above (or below) a certain threshold if the 90% confidence limit on the risk estimate exceeds (or is less than) the threshold”. 
** We suggest that individual results for risk alleles associated with small increase in risk of cancer (as determined by well-powered studies) should not be included in clinical genetic test reports in isolation but 
presented as a combined overall risk prediction score. 
*** We do note that it cannot be assumed that all variants that are associated with increased disease risk will predict (the same) response to targeted therapy and vice versa. It is thus recommended that future 
iterations of multi-tier reporting schemes provide for distinct annotation of germline variants for disease risk and relevance to drug treatment.   
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CONCLUSIONS & FUTURE DIRECTIONS 
 
Our international consortium experience has highlighted that many terms used to 
describe genetic variants have multiple meanings, so that terms may be used 
interchangeably with the potential for false inferences in different contexts. Variant 
descriptor output from bioinformatics tools has potential to lead to patient 
mismanagement if directly transferred into clinical reports without clear explanation. 
Further, there is considerable debate regarding use of terms to describe risk 
association and relevance to clinical management, with particular contention around 
the term pathogenic and relationship with patient medical management. We 
summarize the key points and provide recommendations on variant annotation and 
terminology in Table 5. We also propose a framework for describing variants using a 
vocabulary that may be incorporated into clinical laboratory reporting. If adopted this 
approach should lead to more consistent variant interpretation at the laboratory level 
(ACMG/IARC), and importantly, allow clinical reports to clearly capture the relevance 
of a variant (or combination of variants) for the intended healthcare application.  We 
recognize that practical implementation of such a system would require routine input 
from appropriately trained clinicians before a test report is issued for discussion with 
the patient. By no means intended as a final product, we present this for discussion 




Table 5: Key recommendations regarding variant descriptors and their use in variant 
classification and clinical reporting* 
The term variant should be used to define a DNA change that differs from a defined reference sequence 
It is important to always specify the tissue from which tested DNA has been derived 
Bioinformatic prediction of variant effect on function should not be used alone to infer association with 
measurable disease risk. 
Bioinformatic prediction scores, together with information on variant location in the gene relative to 
splicing motifs/functional domains, may be calibrated against clinical measures of variant pathogenicity 
(termed clinical calibration) to provide probability estimates useful to re-assign a variant as likely not 
pathogenic. 
The term spliceogenic is used generically to describe a variant that results in altered mRNA transcript 
profile (relative to a reference), without consideration of transcript/s susceptibility to NMD, ability to 
encode functional protein, or association with disease risk. 
Variants analyzed in functional assays (biochemical, biophysical, molecular biological, cellular) that 
assess variant effect on protein conformation/stability/activity/function should describe effect compared to 
wildtype and other controls, and always specify the protein effect measured. 
A variant with measurable effect in vitro on mRNA transcript profile or protein function (specifying feature 
measured), relative to appropriate controls, should not be assumed to be associated with quantifiable 
disease risk. 
It is critical to specify disease/phenotype and mode of inheritance when providing a pathogenicity 
assertion for a genetic variant. 
Present variant-associated risks as an absolute measure, and a relative measure, and report these with 
appropriate confidence intervals. 
* Note, variant annotation is a broad term used in the context of next generation sequencing bioinformatic 
pipelines to describe the process of assigning a variety of descriptors to a given sequence variant, but these 
annotations are largely distinct from the clinically-focused variant terminology denoted above. Please see 
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Term/s that may 
be used 
interchangeably 
Alternative uses for descriptors or terms in literature (Some specific source/s noted) 
Mutation  
● Permanent change in the nucleotide sequence [1]. 
● Process by which a change occurs in DNA OR describing sequence changes in specific genes which are known 
to harbor disease-causing changes that result in well recognized heritable disorders (HVP, 
http://www.humanvariomeproject.org). 
● Any germline change (relative to a given reference sequence), sometimes defined as “rare” with variable 
definitions of rare e.g. MAF <1%, <0.1%, <0.001%). 
● Cancer-related change (inferred - relative to a given reference sequence or relative to the germline sequence for 
that individual) (CIVIC, https://civicdb.org/home). 
● Germline sequence variant associated with phenotype of clinical relevance and variant carrier status may be 
used to inform clinical management of probands and/or relatives (NCCN, www.nccn.org; NICE, 
https://www.nice.org.uk; eviQ, https://www.eviq.org.au; CIMBA, http://cimba.ccge.medschl.cam.ac.uk). 
Alteration 
● Any germline change (relative to reference sequence). 
● Any somatic change (relative to reference or germline sequence). 







● Variant associated with/causing dominantly inherited disease. 
● Health-care provider can use the molecular testing information in clinical decision-making (Pathogenic [1]). 
● Variant associated with/causing phenotype of clinical relevance; variant carrier status may be used to inform 
clinical management of probands and/or relatives (Pathogenic, IARC scheme [2]). 
● Variant contributes mechanistically to disease but is not necessarily fully penetrant i.e. may not be sufficient in 
isolation to cause disease (Pathogenic [3]). 
Variant ● Variant significantly associated with increased risk (compared to general population average lifetime risk) of a 
specific disease or diseases, where the relevance of this increased risk to individual clinical management is 









● Variant reduces the reproductive fitness of carriers, and would thus be targeted by purifying natural selection 
(Deleterious [3]). 
● Variant assessed by evolutionary/phylogenetic methods that is conserved in evolutionary space ~ evolutionarily 
unlikely change (Damaging, PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) & SIFT (http://sift-dna.org), See 
Table 1). 
● Descriptor for variant predicted bioinformatically to alter protein structure or function (Damaging, FATHMM, See 
Table 1). 
● Variant that causes loss of protein function, either by impacting mRNA level or transcript profile and/or by 
resulting in a change in encoded protein sequence that affects protein stability, conformation or function 
(Damaging – for loss of protein function [4]). 
● Sequence variant associated with phenotype of clinical relevance and variant carrier status may be used alone 
to inform clinical management of probands and/or relatives (Deleterious, NCCN (www.nccn.org), EMA 
(http://www.ema.europa.eu/), FDA (https://www.fda.gov/)). 
● Descriptor for variant that abrogates or alters the normal levels or biochemical function of a gene or gene 
product, generally determined using in vitro or in vivo assays (Damaging [3 4], Deleterious [5 6], Impacts 
function [7 8]. 
Null Variant;  




● Nonsense, frameshift, canonical +1/2, initiation codon and single exon deletion, multi-exon deletion variant (Null 
[1]). 
● As above, but with multiple other gene-specific considerations and additional details that infer loss of function 
without experimental evidence (LOF, ClinGen Sequence Variant Interpretation Committee, [9]). 
● Variant proven from molecular assays to result in loss of function at the RNA or protein level – due to effect of 




● Germline variant that is significantly associated with risk of disease at a level (generally >2-fold) that may be 
used to alter clinical management in selected circumstances or in consideration with other risk factors e.g. 
prevention for second cancers, for individuals with family history of the disease or other risk modifiers 
(Moderate [11]). 
● Germline variant that is significantly associated with risk of disease that is intermediate between general 
population risk and that of a classical high-risk pathogenic variant in that gene (Intermediate [12 13]; Moderate 
[14]).  
Polymorphism;  
Common Variant;  
SNP, 
SNV 
● A common sequence change (frequency not defined)  
● Germline sequence change not associated with a phenotype of clinical relevance, irrespective of variant 
frequency. 
● Germline sequence change associated with risk of disease, at a level that is not considered clinically relevant, 
on its own, to alter patient management recommendations. 
● Variant with a population frequency above 1% (Polymorphism [1]) 
● Variant assessed by bioinformatic methods that include evolutionary/phylogenetic methods and protein 
structure/function and considered unlikely to alter function/cause disease, irrespective of variant frequency 
(Polymorphism, LRT bioinformatics tool, http://www.genetics.wustl.edu/jflab/lrt_query.html. See Table 1) 
● Single nucleotide polymorphism (SNP) ~ germline single nucleotide substitution sequence variant (frequency 
may not be defined) 
● Single nucleotide variant (SNV) ~ commonly used in the context of high throughput sequencing to describe any 
single nucleotide substitution sequence variant (germline or tumor) 
● Phenomenon in biology, describing discontinuous genetic variation resulting in the occurrence of several 




● Variant not associated with a phenotype of clinical relevance (Neutral, initial integrated evaluation publication 
[16], also [5 7 8]. 
● Variant assessed by evolutionary/phylogenetic methods and not conserved (Tolerated or Neutral, multiple 
bioinformatic tools, See Table 1). 
● Variant that does not cause loss of protein function, either by impacting mRNA level or transcript profile and/or 
by resulting in a change in encoded protein sequence that affects protein stability, conformation or function 
(Tolerated, evolutionarily neutral [17]).  
Benign/Innocuous/ 
Harmless Variant 
● Variant not associated with a phenotype of clinical relevance (Benign, ACMG/AMP, [1] ). 
● Germline change that is significantly associated with a very modest risk of disease as measured using large-
scale genetic studies e.g <1.5-fold or 2-fold, and is not used alone to inform clinical management . 
● Variant that does not cause loss of protein function, either by impacting mRNA level or transcript profile and/or 
by resulting in a change in encoded protein sequence that affects protein stability, conformation or function.  
● Variant assessed by bioinformatic methods and considered unlikely to alter function/cause disease (Benign, 
PolyPhen-2, http://genetics.bwh.harvard.edu/pph2. See Table 1). 
Not pathogenic or 
non-pathogenic 
Variant/ 
Variant of no 
clinical significance/ 
Variant of little 
clinical significance 
● Variant not associated with a phenotype of clinical relevance (Not pathogenic/no clinical significance, IARC 
scheme [2]). 
● Germline variant that is significantly associated with a very modest risk of disease as measured using large-
scale genetic studies e.g <1.5-fold, that is not used alone to inform clinical management (Not pathogenic/no 




Variant of Uncertain 
Clinical 
Significance/ 
Variant of Uncertain 
Significance 
● Variant that has not yet been assessed for its association with phenotype of clinical relevance (Unclassified 
[4]).  
 
● Variant that has been assessed for its association with phenotype of clinical relevance but for which clinical 
significance remains uncertain (Uncertain [4]; Unclassified [19]). 
 
Abbreviations: ACMG – American College of Medical Genetics and Genomics; AMP - Association for Molecular Pathology; CIMBA 
- Consortium of Investigators of Modifiers of BRCA1 and BRCA2; CIViC - Clinical Interpretation of Variants in Cancer; EMA - 
European Medicines Agency; FDA - US Food & Drug administration; HVP – Human Variome Project; LRT – Likelihood Ratio Test; 
MAF - minor allele frequency; NCCN - National Comprehensive Cancer Network; NICE - National Institute for Health and Care 
Excellence; IARC – International Agency for Research into Cancer. 
 
* Note, a sequence variant implicated in risk of another (recessive) disease may be termed pathogenic without considering its 
relevance to the disease being evaluated. Also see Table 4. . 
** In some circumstances a low-risk variant may be misconstrued to be a variant that lowers risk of disease (as opposed to a 
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Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report.   
Spurdle et al, J Medical Genetics. 
 
Supplementary Table 2: Examples of multi-tier reports for variants potentially identified by multi-gene cancer panel testing  
(Relevant genes for example variant reports are ATM (MIM607585), BRCA1 (MIM113705), BRCA2 (MIM600185), CHEK2 (MIM604373). 
 
Demographic Information Female, age 55, no family history 
Cancer Phenotype Breast Cancer 
Sample Tissue √ Blood   
Context √ Diagnostic  √ Prediction Cancer Risk  √ Genotype Directed Treatment  x Other (specify) 
 
Variant Identified NM_007294.3(BRCA1):c.1969C>T p.(Gln657Ter) 
 
Level 1: Variant Classification  
IARC Variant Classification Pathogenic. IARC guidelines for the interpretation and classification of variants present strong evidence that this variant is or may be 
causal for one or more cancer phenotypes including breast and ovarian cancer. Assertion relates to dominant mode of inheritance for 
cancer phenotype. Details of the evidence supporting the variant classification is provided as supplementary documentation.  
 
Level 2: Clinical Validity  
Presenting Cancer Phenotype There is strong evidence that this variant is making a substantial contribution to the presenting cancer phenotype [1]. 
Prediction Cancer Risk There is strong evidence to support the prediction of a high absolute breast and ovarian cancer risk when this variant is present in a family 
member. Based upon prospective study data, the average cumulative lifetime risk is 60% (95% confidence interval (CI) 44%-75%) and the 
average cumulative lifetime risk for ovarian cancer risk is 59% (CI 43-76%) [2 3].  
Genotype Directed Treatment There is evidence to support consideration of PARP inhibitors in the context of breast and ovarian cancer [4]. 
Biallelic Inheritance Rare reported cases of biallelic (compound heterozygote or homozygote) inheritance of BRCA1 pathogenic variants have been reported to 
cause Fanconi Anemia   [5-8] 
 
Level 3: Clinical Utility & 
Actionability 
 
Action This variant is clinically actionable. Refer to clinical genetics service for full evaluation and discussion of risk management options. 
1. High risk breast surveillance. 
2. Eligible to consider risk reducing surgery depending on cancer prognosis and treatment. This may include consideration of BRRM 
[9]. BSO likely to be advised once childbearing complete.  
3. Consideration of precision management with PARP inhibitors and platinum based chemotherapy.  




Demographic Information Female age 30 years, benign breast lump investigated. Concerned about family history 
Cancer Phenotype Unaffected 
Sample Tissue √ Blood   
Context x Diagnostic  √ Prediction Cancer Risk  x Genotype Directed Treatment  x Other (specify) 
 
Variant Identified NM_000059.3(BRCA2):c.5delC p.(Pro2LeufsTer23) 
 
Level 1: Variant Classification  
IARC Variant Classification  Pathogenic. IARC guidelines for the interpretation and classification of variants present strong evidence that this variant is or may be 
causal for one or more cancer phenotypes including breast and ovarian cancer. Assertion relates to dominant mode of inheritance for 
cancer phenotype. Details of the evidence supporting the variant classification are provided as supplementary documentation.  
 
Level 2: Clinical Validity  
Presenting Cancer Phenotype N/A 
Prediction Cancer Risk There is strong evidence to support the prediction of a high absolute breast and ovarian cancer risk when this variant is present in an 
unaffected female. Based upon prospective study data, the average cumulative lifetime risk for breast cancer is 55% (95% confidence 
interval (CI) 41-72%) and for ovarian cancer the average cumulative lifetime risk is 16.5% (CI 7.5-34%) [2 3]. 
Genotype Directed Treatment N/A 
Biallelic Inheritance Evidence supports that biallelic (compound heterozygote or homozygote) variant inheritance causes Fanconi anaemia [10] 
 
Level 3: Clinical Utility & 
Actionability 
 
Action This variant is clinically actionable. Refer to clinical genetics service for full evaluation and discussion of risk management options. 
1. High risk breast surveillance. 
2. Eligible to consider risk reducing surgery depending on cancer prognosis and treatment. This may include consideration of BRRM 
[9]. BSO likely to be advised once childbearing complete.  
3. Consideration of precision management with PARP inhibitors and platinum based chemotherapy if develops cancer.  





Demographic Information Female aged 43 
Cancer Phenotype Breast Cancer 
Sample Tissue √ Blood    
Context √ Diagnostic  √ Prediction Cancer Risk  √  Genotype Directed Treatment  x Other (specify) 
 
Variant Identified NM_007294.3(BRCA1):c.5096G>A p.(Arg1699Gln) 
 
Level 1: Variant Classification  
ACMG Variant Classification Pathogenic. ACMG guidelines for the interpretation and classification of variants present strong evidence that this variant is or may 
be contributing to risk of one or more cancer phenotypes including breast cancer. Assertion relates to dominant mode of inheritance 
for cancer phenotype. Details of the evidence supporting the variant classification are provided as supplementary documentation.  
 
Level 2: Clinical Validity  
Presenting Cancer Phenotype There is strong evidence that this variant is contributing to the presenting cancer phenotype [11]. 
Prediction Cancer Risk There is strong evidence to support a moderate increase in new primary breast and ovarian cancer risk when this variant is present in 
an unaffected family member and can be used for cancer risk stratification [12 13]. The best available estimate of cumulative lifetime 
risk for breast cancer is 20% (95% Confidence Interval (CI) 17 to 24%) and the best available estimate of cumulative lifetime risk for 
ovarian cancer is 6% (CI 4 to 9%)[13]. 
Genotype Directed Treatment Although truncating variants in BRCA1 are associated with tumor sensitivity to targeted treatment with PARP inhibitors, there are no 
published data to support or refute that moderate risk BRCA1 missense variants confer tumor sensitivity to PARP inhibitors. 
Biallelic Inheritance There are no reported cases of Fanconi anaemia due to biallelic (compound heterozygote or homozygote) with this particular variant 
but it remains hypothetically possible. 
 
Level 3: Clinical Utility & 
Actionability 
 
Action This variant is clinically actionable. Refer to clinical genetics service for full evaluation and discussion of risk management options. 
1. Carriers should be offered moderate risk surveillance  
2. Level of risk is not sufficiently high to be eligible for risk reducing breast surgery (estimate 20% by age 70) 
3. Lifetime ovarian cancer risk is 6% and female carriers of this variant could consider risk reducing salpingo-oophorectomy  
4. Insufficient evidence regarding the clinical efficacy of PARP inhibitors but platinum based chemotherapy remains a 
consideration. 




Demographic Information Male, aged 45  
Cancer Phenotype Colorectal Cancer 
Sample Tissue √ Blood    
Context √  Diagnostic  √  Prediction Cancer Risk  √ Genotype Directed Treatment  x Other (specify) 
 
Variant Identified NM_000051.3 (ATM): c.7271T>G p.(Val2424Gly) 
 
Level 1: Variant Classification  
ACMG Variant Classification  Pathogenic.  ACMG guidelines for the interpretation and classification of variants present strong evidence that this variant is or may 
contribute substantially to one or more cancer phenotypes including breast cancer. Assertion relates to dominant mode of inheritance 
for cancer phenotype. Details of the evidence supporting the variant classification are provided as supplementary documentation.  
 
Level 2: Clinical Validity  
Presenting Cancer Phenotype There is insufficient evidence to support an association between this variant and the presenting colorectal cancer phenotype. 
Prediction Cancer Risk There is strong evidence to support the prediction of a high absolute risk of new primary breast cancer when this variant is present in 
a female family member. This magnitude of effect can be in excess of 8-11 fold compared to the basal population risk [14 15]. The 
estimated cumulative lifetime risk of breast cancer is 52% (CI 28% to 80%), and there is no evidence of association of this variant 
with ovarian or prostate cancer risk [15]. 
Genotype Directed Treatment There is currently no evidence to support consideration of precision treatment for pathogenic ATM variant carriers in the context of 
colorectal cancer, but they may be eligible for clinical trials. 
Biallelic Inheritance Evidence may support that biallelic (compound heterozygote or homozygote) variant inheritance is likely to cause Ataxia 
Telangiectasia [16].  
 
Level 3: Clinical Utility & 
Actionability 
 
Action This variant is clinically actionable. Refer to clinical genetics service for full evaluation and discussion of risk management options. 
1. High risk breast surveillance in female carriers 
2. Cascade genetic testing 
3. Bowel cancer risk should be managed according to the family history, with referral to a regional family history service 







Demographic Information Female, aged 48 
Cancer Phenotype Breast Cancer 
Sample Tissue √ Blood    
Context √  Diagnostic  √  Prediction Cancer Risk  √ Genotype Directed Treatment  x Other (specify) 
 
Variant Identified NM_000051.3 (ATM): c.2413C>T p.(Arg805Ter) 
 
Level 1: Variant Classification  
ACMG Variant Classification  Pathogenic.  ACMG guidelines for the interpretation and classification of variants present strong evidence that this variant is or may be 
contributing to breast cancer phenotype. Assertion relates to dominant mode of inheritance for cancer phenotype. 
Details of the evidence supporting the variant classification are provided as supplementary documentation.  
 
Level 2: Clinical Validity  
Presenting Cancer Phenotype There is strong evidence to support an association between protein truncating variants in ATM and the presenting cancer phenotype [17]. 
Prediction Cancer Risk Estimates of cumulative lifetime risk of cancer are not available for ATM c.2413C>T p.(Arg805Ter) specifically. A systematic review and 
meta-analysis of published cancer risk estimate for protein truncating ATM variants shows a small increase in associated risk for a range of 
cancers, but not sufficient to alter screening recommendations above population level. Specifically, there is strong evidence to support the 
prediction of a ~3-fold increased risk of breast cancer, compared to the basal population risk in female gene carriers; the pooled relative 
risk estimate for breast cancer was 3.0 (2.1–4.5) [17]. For a population with a cumulative breast cancer of ~6% to age 70, this relative risk 
would equate to a cumulative risk to age 70 for an ATM carrier of ~18%.This variant should not be considered in isolation. Information from 
the family history of disease, and other known genetic and environmental risk factors or polygenic risk scores may further modify overall 
cancer risk estimates. 
Genotype Directed Treatment There is currently no evidence to support use of pathogenic ATM variant carrier status to predict response to specific drug treatments. 
Biallelic Inheritance Evidence supports biallelic (compound heterozygote or homozygote) variant inheritance is likely to cause Ataxia Telangiectasia [16].  
 
Level 3: Clinical Utility & 
Actionability 
 
Action This variant is clinically actionable but not in isolation. Refer to clinical genetics service and local guidelines where available. A full risk 
evaluation incorporating family history and other known risk factors should inform discussion of risk management options+. 
1. Additional risk surveillance may be required. Clinical management recommendations should be determined on the basis of the 
absolute cancer risks conferred by this variant in combination with the personal and/or family history of disease and other known 
genetic and environmental risk factors 
2. The level of risk for this variant alone is not sufficiently high to advocate risk reducing breast surgery. 
3. Consideration of cascade genetic testing based upon local (regional/national) guidance. 
+High risk surveillance if comprehensive cancer risk (family history based risk) stratification >30% absolute lifetime risk, moderate risk surveillance if comprehensive cancer risk 




Demographic Information Male aged 54,  mother died of breast cancer age 52, two daughters 
Cancer Phenotype N/A 
Sample Tissue √  Blood    
Context x  Diagnostic  √  Prediction Cancer Risk  x Genotype Directed Treatment  x Other (specify) 
 
Variant Identified NM_007194.3 (CHEK2): c.1100delC p.(Thr367Metfs) 
 
Level 1: Variant Classification  
ACMG Variant Classification  Pathogenic. ACMG guidelines for the interpretation and classification of variants present strong evidence that this variant is or may be 
contributing to one or more cancer phenotypes including breast cancer. Assertion relates to dominant mode of inheritance for cancer 
phenotype.  Details of the evidence supporting the variant classification are provided as supplementary documentation.  
 
Level 2: Clinical Validity  
Presenting Cancer Phenotype N/A 
Prediction Cancer Risk There is strong evidence to support a moderate increase in breast cancer risk associated with CHEK2 c.1100delC p.(Thr367Metfs) when 
this variant is present in a family member, and it can be used for cancer risk stratification. The risk is generally considered to be 2-3 fold 
above baseline population risk [18-20]. For a population with a cumulative breast cancer of ~6% to age 70, this equates to a cumulative risk 
to age 70 for a carrier of this variant of ~12-18%. Risk for carriers of this variant should not be considered in isolation. Information from the 
family history of breast cancer , and other known genetic and environmental risk factors or polygenic risk scores may further modify overall 
cancer risk estimates [20 21].  
Genotype Directed Treatment N/A 
Biallelic Inheritance Biallelic mutation carriers have a high absolute lifetime risk of breast cancer [22] . 
 
Level 3: Clinical Utility & 
Actionability 
 
Action This variant is clinically actionable but not in isolation. Refer to clinical genetics service and local guidelines where available. A full risk 
evaluation incorporating family history and other known risk factors should inform discussion of risk management options+. 
1. Additional risk surveillance may be required in female carriers. Clinical management recommendations should be determined on 
the basis of the absolute cancer risks conferred by <variant identified> in combination with the personal and/or family history of 
disease and other known genetic and environmental risk factors 
2. The level of risk for this variant alone is not sufficiently high to advocate risk reducing breast surgery. 
3. Consideration of cascade genetic testing based on local (regional/national) guidance. 
+High risk surveillance if comprehensive cancer risk (family history based risk) stratification >30% absolute lifetime risk, moderate risk surveillance if comprehensive cancer risk 





Demographic Information Female aged 40, twins by IVF age 2 years. 
Cancer Phenotype N/A 
Sample Tissue √  Blood    
Context x  Diagnostic  √  Prediction Cancer Risk  x Genotype Directed Treatment x Other (specify) 
 
Variant Identified NM_007194.3 (CHEK2): c.470T>C p.(Ile157Thr) 
 
Level 1: Variant Classification  
ACMG Variant Classification  
 
Little clinical significance / Benign. Population studies show this sequence variant is associated with a low increased risk of cancer [23 24]. 
Assertion relates to dominant mode of inheritance for cancer phenotype.  
Details of the evidence supporting the variant classification are provided as supplementary documentation.  
 
Level 2: Clinical Validity  
Presenting Cancer Phenotype N/A 
Prediction Cancer Risk There is strong evidence from large population studies to support a low increase in breast cancer risk, but the variant cannot be used in isolation 
for cancer risk prediction. The frequency of this variant is significantly higher amongst unselected female breast cancer patients compared with 
the expected population frequencies with an estimated magnitude of breast cancer risk which is approximately 1.5 fold compared to the basal 
population level [23-25]. This variant alone is unhelpful in predicting cancer risk for an individual. 
Genotype Directed Treatment N/A 
Biallelic Inheritance There are no data available regarding the impact of biallelic inheritance of this specific variant on cancer risk or risk for other phenotypes. 
 
Level 3: Clinical Utility & Actionability  
Action This variant is not clinically actionable. 
1. Manage Based Upon Family History. This variant is insufficiently predictive of individual cancer risk to be clinically actionable. Clinical 
management recommendations should be determined on the basis of personal and/or family history of disease and other known risk 
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SUPPLEMENTARY TEXT: Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA 
report.  Spurdle et al, J Medical Genetics. 
 
ENIGMA membership 
Eligibility for membership is broad: an ENIGMA member is currently defined as a researcher or research group (consortium) who is 
willing to work collaboratively towards classification of variants by contributing data from families and/or conducting statistical analysis 
or laboratory-based assays within a working group framework, namely clinical, analytical, functional, splicing and pathology working 
groups. The ENIGMA membership listing currently includes 309 individuals from 38 different countries. Most of these members (202) 
are from countries where research and clinical activities are conducted in a language other than English (see Supp Figure 1). 
 
Supplementary Figure 1:  Heatmap showing distribution of ENIGMA members across countries. 
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Published recommendations on variant terminology 
 
ACMG/AMP [1]: “The terms “mutation” and “polymorphism,” however, which have been 
used widely, often lead to confusion because of incorrect assumptions of pathogenic 
and benign effects, respectively. Thus, it is recommended that both terms be replaced 
by the term “variant” with the following modifiers: (i) pathogenic, (ii) likely pathogenic, 
(iii) uncertain significance, (iv) likely benign, or (v) benign.” 
HVP [2]: “The term “variant” should be used to describe all sequences changes 
irrespective of their contribution to phenotype. Mutation may be used in the correct 
sense of the word to describe the process by which variants arise. Use of the term 
polymorphism is deprecated.”  
It is also the term used in publication to describe somatic alterations by the Variant 
Interpretation for Cancer Consortium (VICC) [3], although the terminology seems not to 
be transferred to the CIViC web-based resource for expert crowdsourcing of Clinical 
Interpretation of Variants in Cancer (http://civicdb.org/), a key output from this group. 
 
 
Clinical calibration, replication and validation 
 
Clinical calibration refers to the process where a specific type of information (e.g. 
bioinformatic score, protein function, splicing aberration, pathology information) is 
calibrated as a measure of variant pathogenicity against clinical predictors of variant 
pathogenicity (e.g. segregation data, family history profile, frequency in population 
controls).  For example, Easton et al [4] provides an assessment of family history 
profiles of BRCA1/2 pathogenic variant carriers versus non-carriers, according to variant 
location in specific motifs or domains, combined with bioinformatic prediction of 
missense effect. To avoid over-fitting, we recommend that initial calibration of a 
promising predictive measure (in particular functional assays) should be followed by a 
validation study using an independent set of variants, or at least an independent patient 
observational dataset. Further, as shown in Supplementary Figure 2 below, and 
utilized in Drost et al [5], we suggest the following approach to describe replication and 
validation of a clinical calibration exercise. A functional assay method and its calibration 
can be considered to be replicated, but not validated, if at least one point estimated 
from the Training and Validation sets falls outside the other point estimate's 80% 
Confidence Interval (CI), but the point estimates are mutually within their 95% CI, which 
are wider. In this case, the method’s point estimates and confidence intervals will be 
refined by recalculation from the combined data set; in this scenario it may be 
considered appropriate to withhold the method from quantitative clinical use until it has 
met the stricter criterion for replication and validation against a later data set. A method 
and its calibration are considered invalidated if either or both point estimates fall outside 




Supplementary Figure 2:  
Depiction of confidence interval-
based assay validation logic. 
 
Blue ball: point estimate. 
Blue line: 80% confidence limits. 
Yellow line: 95% confidence 
limits. 
a. Replicated and validated. 







Definitions of key terms used to describe the clinical importance of sequence 
variation.  
 
Definitions, including health-related definitions where available, were sourced by online 
searches of the Oxford, Collins and Merriam-Webster dictionaries. Derivations were 
synthesized from all three sources. Considerations about translations of these terms 
into other languages was discussed by ENIGMA members whose primary language 
was not English. 
 
Pathogenic:  
Oxford: (of a bacterium, virus, or other microorganism) causing disease. 
Collins: able to cause or produce disease (British), producing disease (American). 
Merriam-Webster: Causing or capable of causing disease. 
Derivation: From the Greek pathos (suffering) + gen (that which produces). 
 
Deleterious: 
Oxford: causing harm or damage 
Collins: harmful, injurious, hurtful (English), harmful to health or well-being, injurious 
(American). 
Merriam-Webster: damaging or harmful, or harmful often in a subtle or unexpected way 
(medical definition). 
Derivation: via Medieval Latin from Greek deleterios (noxious/injurious/destructive).  
 




Oxford: (of a disease) not harmful in effect; (of a tumour) not malignant. 
Collins: not threatening to life or health; not malignant (British), doing little or no harm, 
not malignant (American). 
Merriam-Webster: of a mild type or character that does not threaten health or life 
(especially, not becoming cancerous); having no significant effect.  
Derivation: Middle English - from Old French benigne, from Latin benignus, (probably) 
from bene (well) + -genus (-born). Alternative derivation (Collins) - from Old French 
benigne, from Latin benignus, from bene (well) + gignere (to produce). 
 
Mutation:   
Oxford: the process or an instance of change or alteration; a genetic change which, 
when transmitted to offspring, gives rise to heritable variations (Australian), action or 
process of mutating, changing of the structure of a gene – resulting in a variant form 
that may be transmitted to subsequent generations; a distinct form resulting from 
genetic mutation (English). 
Collins: the act or process of mutating, change, alteration; a change or alteration; a 
change in the chromosomes or genes of a cell, which when in gametes the structure 
and development of the resultant offspring may be affected (English). a changing or 
being changed; a change as in form, nature, qualities; a sudden variation in some 
inheritable characteristic in a germ cell of an individual animal or plant, as distinguished 
from a variation resulting from generations of gradual change; an individual resulting 
from such variation; an abrupt and relatively permanent change in somatic cells that is 
transmitted only to daughter cell and can be inherited only in plants that reproduce 
asexually (American). 
Merriam-Webster: a significant and basic alteration; a relatively permanent change in 
hereditary material that involves either a change in chromosome structure or number or 
a change in the nucleotide sequence of a gene's codons (as in frameshift or missense 
errors) and that occurs either in germ cells or in somatic cells but with only those in 
germ cells being capable of perpetuation by sexual reproduction; an individual, strain, or 
trait resulting from mutation 
Derivation: Middle English from Latin mutatio, from mutare (change). 
 
Significance:  
Oxford: the quality of being worthy of attention, important. 
Collins: consequence or importance. 
Merriam-Webster: quality of being important, the quality of having notable worth or 
influence. 
Derivation: Middle English via Old French significance, from Latin significantia, from 






Annotation based on variant sequence/position and (predicted) effect on 
gene/protein product 
 
Variant annotation, often used in the context of next generation sequencing 
bioinformatic pipelines, is the process of assigning various descriptors or data points 
relevant for a given sequence variant. The purpose is to assess variously: the quality of 
a sequence variant call; the location of a variant in relation to functional genomic 
regions (exons, introns, splice sites, regulatory sites); bioinformatically predicted effect 
on mRNA transcript/encoded protein, nucleotide protein or evolutionary conservation; 
and multiple other possible features used to interpret the clinical or research importance 
of genetic variation. As an example, Variant Effect Predictor (VEP,  [6]) is applied 
commonly in sequencing pipelines, and uses sequence ontology (SO) terms [7] to 
describe a genomic variant by type of sequence alteration, genomic features altered by 
the change, and the predicted impact of the alteration. Pipelines may also include cross-
reference to identify the variant (or variant position) in internal or external datasets that 
provide information used for curation of disease gene variants against recognized 
variant classification criteria. For example: variant frequency in outbred population 
groups such as gnomAD (http://gnomad.broadinstitute.org/)[8]; presence and 
pathogenicity assertion in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) [9], presence 
in the COSMIC repository of variation identified in tumors (Catalogue of Somatic 
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